Literature DB >> 27358874

Mesenchymal stem cells as delivery vectors for anti-tumor therapy.

Zhenzhen Li1, Dongmei Fan1, Dongsheng Xiong1.   

Abstract

Recent studies have demonstrated mesenchymal stem cells (MSCs) are able to migrate specifically to tumors and their metastatic sites when administered intravenously. This characteristic tumor tropism has opened up an emerging field to utilize MSCs as vectors to deliver anti-cancer agents for targeted therapies. Genetically engineered MSCs can specifically migrate to various tumors and locally secrete therapeutic proteins, such as interferon β (IFN-β) and IFN-γ, interleukin 12 and 24, tumor necrosis factor-related apoptosis inducing ligand (TRAIL) or suicide gene/enzyme prodrug. In addition, MSCs have also been engineered to deliver oncolytic viruses and drug-loaded nanoparticles. Here, we present the characteristics of MSCs, the current progress on MSC mediated anti-cancer agents delivery systems and the interaction between MSCs and tumors.

Entities:  

Keywords:  Mesenchymal stem cell (MSC); cancer therapy; delivery vector

Year:  2015        PMID： 27358874      PMCID： PMC4923660          DOI： 10.3978/j.issn.2306-9759.2015.03.01

Source DB:  PubMed          Journal:  Stem Cell Investig        ISSN： 2306-9759


  44 in total

1.  An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies.

Authors:  Carlos Almeida Ramos; Zahra Asgari; Enli Liu; Eric Yvon; Helen E Heslop; Clio M Rooney; Malcolm K Brenner; Gianpietro Dotti
Journal:  Stem Cells       Date:  2010-06       Impact factor: 6.277

2.  Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma.

Authors:  Mariam A Stoff-Khalili; Angel A Rivera; J Michael Mathis; N Sanjib Banerjee; Amanda S Moon; A Hess; Rodney P Rocconi; T Michael Numnum; M Everts; Louise T Chow; Joanne T Douglas; Gene P Siegal; Zeng B Zhu; Hans Georg Bender; Peter Dall; Alexander Stoff; Larissa Pereboeva; David T Curiel
Journal:  Breast Cancer Res Treat       Date:  2007-01-13       Impact factor: 4.872

3.  Therapeutic efficacy and fate of bimodal engineered stem cells in malignant brain tumors.

Authors:  Jordi Martinez-Quintanilla; Deepak Bhere; Pedram Heidari; Derek He; Umar Mahmood; Khalid Shah
Journal:  Stem Cells       Date:  2013-08       Impact factor: 6.277

4.  Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy.

Authors:  Ryosuke Uchibori; Takashi Okada; Takayuki Ito; Masashi Urabe; Hiroaki Mizukami; Akihiro Kume; Keiya Ozawa
Journal:  J Gene Med       Date:  2009-05       Impact factor: 4.565

5.  Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.

Authors:  Matus Studeny; Frank C Marini; Richard E Champlin; Claudia Zompetta; Isaiah J Fidler; Michael Andreeff
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

6.  Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma.

Authors:  Cihui Yan; Shuangjing Li; Zhenzhen Li; Hongwei Peng; Xiangfei Yuan; Linlin Jiang; Yanjun Zhang; Dongmei Fan; Xiao Hu; Ming Yang; Dongsheng Xiong
Journal:  Mol Pharm       Date:  2012-12-07       Impact factor: 4.939

Review 7.  Cell and gene therapy using mesenchymal stem cells (MSCs).

Authors:  Keiya Ozawa; Kazuya Sato; Iekuni Oh; Katsutoshi Ozaki; Ryosuke Uchibori; Yoko Obara; Yuji Kikuchi; Takayuki Ito; Takashi Okada; Masashi Urabe; Hiroaki Mizukami; Akihiro Kume
Journal:  J Autoimmun       Date:  2008-01-31       Impact factor: 7.094

8.  Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer.

Authors:  Emily K Mader; Greg Butler; Sean C Dowdy; Andrea Mariani; Keith L Knutson; Mark J Federspiel; Stephen J Russell; Evanthia Galanis; Allan B Dietz; Kah-Whye Peng
Journal:  J Transl Med       Date:  2013-01-24       Impact factor: 5.531

Review 9.  Fetal stem cells from extra-embryonic tissues: do not discard.

Authors:  Akiva J Marcus; Dale Woodbury
Journal:  J Cell Mol Med       Date:  2008-01-11       Impact factor: 5.310

Review 10.  Mesenchymal stem cells migration homing and tracking.

Authors:  Abhishek Sohni; Catherine M Verfaillie
Journal:  Stem Cells Int       Date:  2013-09-30       Impact factor: 5.443
View more
  16 in total

Review 1.  In-vitro blood-brain barrier modeling: A review of modern and fast-advancing technologies.

Authors:  Farzane Sivandzade; Luca Cucullo
Journal:  J Cereb Blood Flow Metab       Date:  2018-07-30       Impact factor: 6.200

2.  Maximized nanodrug-loaded mesenchymal stem cells by a dual drug-loaded mode for the systemic treatment of metastatic lung cancer.

Authors:  Sen Yao; Xuqian Li; Jingxuan Liu; Yuqing Sun; Zhuanhe Wang; Yanyan Jiang
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

3.  E1A-engineered human umbilical cord mesenchymal stem cells as carriers and amplifiers for adenovirus suppress hepatocarcinoma in mice.

Authors:  Zhenzhen Li; Zhou Ye; Xiaolong Zhang; Qing Zhang; Dongmei Fan; Yanjun Zhang; Hongbo R Luo; Xiangfei Yuan; Zongfang Li; Dongsheng Xiong
Journal:  Oncotarget       Date:  2016-08-09

4.  Nanoparticle delivery to metastatic breast cancer cells by nanoengineered mesenchymal stem cells.

Authors:  Liga Saulite; Karlis Pleiko; Ineta Popena; Dominyka Dapkute; Ricardas Rotomskis; Una Riekstina
Journal:  Beilstein J Nanotechnol       Date:  2018-01-29       Impact factor: 3.649

Review 5.  Tumor-educated mesenchymal stem cells promote pro-metastatic phenotype.

Authors:  Billy Samuel Hill; Alessandra Pelagalli; Nunzia Passaro; Antonella Zannetti
Journal:  Oncotarget       Date:  2017-08-14

6.  Fe-Cr-Nb-B ferromagnetic particles with shape anisotropy for cancer cell destruction by magneto-mechanical actuation.

Authors:  H Chiriac; E Radu; M Țibu; G Stoian; G Ababei; L Lăbușcă; D-D Herea; N Lupu
Journal:  Sci Rep       Date:  2018-08-01       Impact factor: 4.379

7.  Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells.

Authors:  Yuanyuan Yang; Xiaolong Zhang; Fangzhen Lin; Mengshang Xiong; Dongmei Fan; Xiangfei Yuan; Yang Lu; Yuewen Song; Yizi Zhang; Mu Hao; Zhou Ye; Yanjun Zhang; Jianxiang Wang; Dongsheng Xiong
Journal:  J Hematol Oncol       Date:  2019-04-25       Impact factor: 17.388

Review 8.  Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer.

Authors:  Rebeca Gonzalez-Pastor; Peter S Goedegebuure; David T Curiel
Journal:  Cancer Gene Ther       Date:  2020-09-19       Impact factor: 5.987

Review 9.  Mesenchymal stem cells as professional actors in gastrointestinal cancer therapy: From Naïve to genetically modified.

Authors:  Mehrdad Nasrollahzadeh Sabet; Masood Movahedi Asl; Mahtab Kazemi Esfeh; Navid Nasrabadi; Maryam Shakarami; Behrang Alani; Asma Alimolaie; Sara Azhdari; Ebrahim Cheraghi
Journal:  Iran J Basic Med Sci       Date:  2021-05       Impact factor: 2.699

10.  pIL6-TRAIL-engineered umbilical cord mesenchymal/stromal stem cells are highly cytotoxic for myeloma cells both in vitro and in vivo.

Authors:  Paola Cafforio; Luigi Viggiano; Francesco Mannavola; Eleonora Pellè; Concetta Caporusso; Eugenio Maiorano; Claudia Felici; Francesco Silvestris
Journal:  Stem Cell Res Ther       Date:  2017-09-29       Impact factor: 6.832
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.